SLC2A1 and breast carcinoma: Moreover, EGFR signalling in breast cancer cells increases c-Myc expression (Iqbal et al., 2021), HK2 activity (Jung et al., 2019), and GLUT1 plasma membrane localisation (Jung et al., 2019), while decreasing expression of TXNIP (Iqbal et al., 2021).